Language:

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Journal of clinical oncology, 2013-10, Vol.31 (30), p.3791-3799 [Peer Reviewed Journal]

2014 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.47.4940 ;PMID: 24019545

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Author: MOTZER, Robert J ; NOSOV, Dmitry ; KOGAN, Mikhail ; ALEKSEEV, Boris Y ; STERNBERG, Cora N ; SZCZYLIK, Cezary ; CELLA, David ; IVANESCU, Cristina ; KRIVOSHIK, Andrew ; STRAHS, Andrew ; ESTEVES, Brooke ; BERKENBLIT, Anna ; EISEN, Timothy ; HUTSON, Thomas E ; BONDARENKO, Igor ; LESOVOY, Vladimir ; LIPATOV, Oleg ; TOMCZAK, Piotr ; LYULKO, Oleksiy ; ALYASOVA, Anna ; HARZA, Mihai
Subjects: Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - surgery ; Disease-Free Survival ; Female ; Health Status ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoadjuvant Therapy - methods ; Neoplasm Staging ; Nephrectomy ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Odds Ratio ; ORIGINAL REPORTS ; Phenylurea Compounds - therapeutic use ; Quality of Life ; Quinolines - therapeutic use ; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors ; Treatment Outcome
Is Part Of: Journal of clinical oncology, 2013-10, Vol.31 (30), p.3791-3799
Description: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC). Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therapies for metastatic RCC were randomly assigned to tivozanib or sorafenib. Prior VEGF-targeted therapy and mammalian target of rapamycin inhibitor were not permitted. The primary end point was progression-free survival (PFS) by independent review. A total of 517 patients were randomly assigned to tivozanib (n = 260) or sorafenib (n = 257). PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042). One hundred fifty-six patients (61%) who progressed on sorafenib crossed over to receive tivozanib. The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105). Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%). AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%). Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.
Publisher: Alexandria, VA: American Society of Clinical Oncology
Language: English;Russian
Identifier: ISSN: 0732-183X
EISSN: 1527-7755
DOI: 10.1200/JCO.2012.47.4940
PMID: 24019545
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

2014 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.47.4940 ;PMID: 24019545

Searching Remote Databases, Please Wait